JAPAN TISSUE ENGINEERING CO., LTD. Japan Tissue Engineering Co., Ltd. Share Price
Equities
7774
JP3389610001
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 590 JPY | -2.48% |
|
-7.23% | +16.60% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 251.4Cr 1.61Cr 134.09Cr | Sales 2025 * | 439.3Cr 2.81Cr 234.32Cr | Capitalization | 2.4TCr 15Cr 1.28TCr |
|---|---|---|---|---|---|
| Net income 2024 | 14Cr 9L 7.63Cr | Net income 2025 * | 96Cr 61.28L 51Cr | EV / Sales 2024 | 11 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.45 x |
| P/E ratio 2024 |
193
x | P/E ratio 2025 * |
25
x | Employees | 215 |
| Yield 2024 * |
1.69% | Yield 2025 * |
1.69% | Free-Float | 27.9% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.48% | ||
| 1 week | -7.23% | ||
| Current month | -10.74% | ||
| 1 month | -18.51% | ||
| 3 months | +19.92% | ||
| 6 months | +16.37% | ||
| Current year | +16.60% |
1 week
585.00
629.00
1 month
585.00714.00
Current year
482.00811.00
1 year
472.00811.00
3 years
451.00859.00
5 years
447.001 028.00
10 years
447.001 977.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ken-ichiro Hata
PSD | President | 59 | 01/04/01 |
Masukazu Iie
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | 67 | 01/07/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Toshihiro Osuka
BRD | Director/Board Member | 67 | 01/99/01 |
Ken-ichiro Hata
PSD | President | 59 | 01/04/01 |
Yukio Mori
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/04/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 590 | -2.48% | 94 800 |
| 13/24/13 | 605 | -2.89% | 40,500 |
| 10/24/10 | 623 | +1.30% | 9,500 |
| 09/24/09 | 615 | -0.65% | 14,300 |
| 08/24/08 | 619 | -0.96% | 12,200 |
Delayed Quote Japan Exchange, May 14, 2024 at 11:30 am IST
More quotes
Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.
Calendar
31/07/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.60% | 16Cr | |
| +8.06% | 12TCr | |
| -5.61% | 1.1TCr | |
| +4.83% | 888.06Cr | |
| +35.04% | 545.48Cr | |
| -22.61% | 474.19Cr | |
| +8.10% | 343.51Cr | |
| -6.00% | 283.63Cr | |
| -10.23% | 215.38Cr | |
| -5.99% | 211.04Cr |
- Stock Market
- Equities
- 7774 Stock
